Gregoire Sylvie 4

What Happened
Gregoire Sylvie, reported as a 10% owner of CervoMed Inc. (CRVO), disclosed a grant/award of 75,000 derivative shares on 2026-02-11. The filing lists the award at $0.00 per share (no cash paid reported). Footnotes state the award consists of an option granted to the Reporting Person's spouse, John Alam, M.D., CervoMed’s President & CEO; the Reporting Person disclaims beneficial ownership of these securities.

Key Details

• Transaction type/date: Award (Code A) on 2026-02-11; filed 2026-02-13 (filed within the typical two-business-day window).
• Amount and price: 75,000 shares (derivative) at $0.00 per share (no purchase price reported).
• Vesting: Under Footnote F2, the underlying shares vest in 36 equal (or near-equal) monthly installments on the last calendar day of each month, commencing February 28, 2026.
• Beneficial ownership: Footnote F1 states the award is an option granted to John Alam (the Reporting Person’s spouse and CEO); Gregoire Sylvie disclaims beneficial ownership.
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: Report appears timely (filed within two business days of the transaction).

Context
This is a derivative award (an option) rather than a direct cash purchase or sale. Because the option vests monthly over three years, the shares will be issued gradually if vested and exercised in the future. The reporting person’s disclaimer and the footnote that the grant was to the spouse mean this report reflects family-related reporting obligations rather than a direct personal purchase; such grants to executives are common as compensation and do not by themselves indicate immediate buying or selling activity.